53 related articles for article (PubMed ID: 15811869)
1. Critical insights into the evolving drug-approval process in China.
Nikanjam M; Kurzrock R
Cancer; 2024 Mar; 130(5):665-667. PubMed ID: 38165313
[TBL] [Abstract][Full Text] [Related]
2. Concerns That May Limit the Utility of Zuranolone.
Prasad V; Allely D
JAMA; 2024 Jan; 331(2):105-106. PubMed ID: 38100400
[TBL] [Abstract][Full Text] [Related]
3. Keeping Safe and Effective Medications Accessible.
Mazer-Amirshahi M; Ye P; Stolbach A
J Med Toxicol; 2023 Jul; 19(3):244-245. PubMed ID: 37233913
[No Abstract] [Full Text] [Related]
4. Upcoming market catalysts in Q3 2023.
Jabbar S
Nat Rev Drug Discov; 2023 Jul; 22(7):528. PubMed ID: 37316649
[No Abstract] [Full Text] [Related]
5. The Next Chapter of Renal Denervation After US Food and Drug Administration Approval.
Vongpatanasin W; Addo T
Circulation; 2024 Mar; 149(10):760-763. PubMed ID: 38437485
[No Abstract] [Full Text] [Related]
6. Unraveling the autoimmune translational research process layer by layer.
Blumberg RS; Dittel B; Hafler D; von Herrath M; Nestle FO
Nat Med; 2012 Jan; 18(1):35-41. PubMed ID: 22227670
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Tp-Te interval, Tp-Te/QTc ratio, and QT dispersion in patients with Turner syndrome.
Atıcı A; Panç C; Karaayvaz EB; Demirkıran A; Kutlu O; Kaşalı K; Kekeç E; Sarı L; Akyol Sarı ZN; Bilge AK
Anatol J Cardiol; 2018 Aug; 20(2):93-99. PubMed ID: 30088483
[TBL] [Abstract][Full Text] [Related]
8. Widening the path and window of opportunity for FDA approval of non-vitamin K oral anticoagulant specific antidotes and reversal agents.
Patel S; Steen D
J Thromb Thrombolysis; 2016 Feb; 41(2):285-92. PubMed ID: 26374107
[TBL] [Abstract][Full Text] [Related]
9. A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors.
Shah RR; Roberts SA; Shah DR
Br J Clin Pharmacol; 2013 Sep; 76(3):396-411. PubMed ID: 23362829
[TBL] [Abstract][Full Text] [Related]
10. High-precision recording of the action potential in isolated cardiomyocytes using the near-infrared fluorescent dye di-4-ANBDQBS.
Warren M; Spitzer KW; Steadman BW; Rees TD; Venable P; Taylor T; Shibayama J; Yan P; Wuskell JP; Loew LM; Zaitsev AV
Am J Physiol Heart Circ Physiol; 2010 Oct; 299(4):H1271-81. PubMed ID: 20601458
[TBL] [Abstract][Full Text] [Related]
11. The FDA regulatory process for drug and genetic diagnostic test approvals.
Bristow MR; Hiatt WR
Clin Transl Sci; 2008 Dec; 1(3):188-9. PubMed ID: 20443847
[No Abstract] [Full Text] [Related]
12. Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings.
Cook DM; Gurugubelli RK; Bero LA
Drug Saf; 2009; 32(11):1057-66. PubMed ID: 19810777
[TBL] [Abstract][Full Text] [Related]
13. QTc interval prolongation in children with Turner syndrome: the results of exercise testing and 24-h ECG.
Dalla Pozza R; Bechtold S; Urschel S; Netz H; Schwarz HP
Eur J Pediatr; 2009 Jan; 168(1):59-64. PubMed ID: 18392639
[TBL] [Abstract][Full Text] [Related]
14. QTc interval prolongation in children with Ulrich-Turner syndrome.
Dalla Pozza R; Bechtold S; Kääb S; Buckl M; Urschel S; Netz H; Schwarz HP
Eur J Pediatr; 2006 Dec; 165(12):831-7. PubMed ID: 16835756
[TBL] [Abstract][Full Text] [Related]
15. Class effects and labeling of antihypertensive drugs.
Pickering TG
J Clin Hypertens (Greenwich); 2006 Mar; 8(3):215-20. PubMed ID: 16523001
[No Abstract] [Full Text] [Related]
16. The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process.
Roden DM; Temple R
Circulation; 2005 Apr; 111(13):1697-702. PubMed ID: 15811869
[No Abstract] [Full Text] [Related]
17. Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003.
Borer J; Armstrong P;
Circulation; 2003 Jun; 107(23):e9052. PubMed ID: 12814989
[No Abstract] [Full Text] [Related]
18. Molecularly targeted oncology therapeutics and prolongation of the QT interval.
Strevel EL; Ing DJ; Siu LL
J Clin Oncol; 2007 Aug; 25(22):3362-71. PubMed ID: 17664484
[TBL] [Abstract][Full Text] [Related]
19. New drugs and product approvals from 2000.
Taylor SE; Gage TW
Tex Dent J; 2001 Nov; 118(11):1070-81. PubMed ID: 11806330
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
